Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of Los Angeles Times, shared on X:
“To be clear these patients with complete responses in Waldenstrom did not undergo the standard of care lymphodepletion..,meaning the trial we are running is entirely chemo free CSSIFM. The patients are receiving our targeted NK cell therapy and Anktiva plus a targeted Antibody.”
More insights from Patrick Soon-Shiong.